Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species
Data indicate that anti-CD137 (show TNFRSF9 ELISA Kits) agonists can function as inhibitors of CD137L signaling, resulting in the creation of tumor microenvironments unfavorable for tumor immune evasion.
Constitutive interaction between 4-1BB (show TNFRSF9 ELISA Kits) and 4-1BBL on murine LPS (show TLR4 ELISA Kits)-activated bone marrow dendritic cells masks detection of 4-1BBL by TKS (show PTK6 ELISA Kits)-1 but not 19H3 antibody.
4-1BBL can restrain effector T cell development, creating a more favorable regulatory T cell to effector cell balance under tolerogenic conditions, and this may be particularly active in mucosal barrier tissues
These results demonstrate that 4-1BBL-engineered DCs can improve CIKs (show TRAF3IP2 ELISA Kits) cytotoxicity against prostate cancer cells.
these observations suggest that inhibition of the TLR/4 (show TLR4 ELISA Kits)-1BBL complex formation may be highly efficient in protecting against continued inflammation
4-1BB (show TNFRSF9 ELISA Kits) mediates the inflammatory responses in obese skeletal muscle by interacting with its ligand 4-1BBL on macrophages.
CD137 (show TNFRSF9 ELISA Kits)-CD137L interactions mediated via regulation of CyPA (show PPIA ELISA Kits) contribute to the progression of atherosclerosis.
Data indicate that CD137L deficient mice displayed a variety of immunological dysfunctions.
monocytes interact with iNKT cells to increase expression of 4-1BBL and 4-1BB (show TNFRSF9 ELISA Kits), and in conjunction with this pathway, maintain their numbers at baseline.
CD137 (show TNFRSF9 ELISA Kits)-expressing CD4 (show CD4 ELISA Kits)+ T cells in the bone marrow engage CD137L on hematopoietic progenitor cells, and this CD137L signaling biases hematopoiesis towards myelopoiesis during aging.
blocking of both OX-40L (show TNFSF4 ELISA Kits) and 4-1BBL reversed radiation-enhanced T-cell killing of human tumor targets as well as T-cell survival and activation.
CD137L is overexpressed in non-small cell lung cancer specimens and positive expression of CD137L was associated with better overall survival.
In vitro immunotherapy is described for anti-prostate cancer effects of cytotoxic T lymphocytes induction by recombinant adenovirus mediated PSMA/4 (show PSMA4 ELISA Kits)-1BBL dendritic cells.
vaccination with recombinant attenuated Salmonella harboring the CEACAM6 and 4-1BBL gene efficiently increased the number of CD3 (show CD3 ELISA Kits)+CD8 (show CD8A ELISA Kits)+ TIL (show TLR1 ELISA Kits) and NK cells, decreased the number of FOXP3 (show FOXP3 ELISA Kits) cells and inhibited the development of DMH (show DST ELISA Kits)-induced colorectal cancer
Elevated plasma levels and monocyte-associated expression of CD137 (show TNFRSF9 ELISA Kits) ligand in patients with acute atherothrombotic stroke
Hence, the targeted combination of IL-15 (show IL15 ELISA Kits) and 4-BBL (show TP53 ELISA Kits) in the form of a trifunctional antibody-fusion protein is a promising new approach for cancer immunotherapy.
TIRAP (show TIRAP ELISA Kits) and IRAK2 (show IRAK2 ELISA Kits) are critical for the sustained inflammatory response that is mediated by late-phase signaling by the TLR-4 (show TLR4 ELISA Kits)-1BBL complex.
this is the first study to indicate that this member of the TNF (show TNF ELISA Kits) superfamily, CD137 (show TNFRSF9 ELISA Kits), is modulated by SAHA treatment in breast
Data show that TNFR1 (show TNFRSF1A ELISA Kits) associates with CD137L and is required for CD137L reverse signaling.
The protein encoded by this gene is a cytokine that belongs to the tumor necrosis factor (TNF) ligand family. This transmembrane cytokine is a bidirectional signal transducer that acts as a ligand for TNFRSF9/4-1BB, which is a costimulatory receptor molecule in T lymphocytes. This cytokine and its receptor are involved in the antigen presentation process and in the generation of cytotoxic T cells. The receptor TNFRSF9/4-1BB is absent from resting T lymphocytes but rapidly expressed upon antigenic stimulation. The ligand encoded by this gene, TNFSF9/4-1BBL, has been shown to reactivate anergic T lymphocytes in addition to promoting T lymphocyte proliferation. This cytokine has also been shown to be required for the optimal CD8 responses in CD8 T cells. This cytokine is expressed in carcinoma cell lines, and is thought to be involved in T cell-tumor cell interaction.
, tumor necrosis factor (ligand) superfamily, member 9
, 4-1BB ligand
, tumor necrosis factor ligand superfamily member 9
, homolog of mouse 4-1BB-L
, receptor 4-1BB ligand